degarelix

Known as: N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide 
A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved… (More)
  • figure 1
Is this relevant?
2012
2012
UNLABELLED Study Type--Therapy (RCT) Level of Evidence 1b. What's known on the subject? and What does the study add? Androgen… (More)
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE To evaluate the efficacy and safety of degarelix, a new gonadotrophin-releasing hormone (GnRH) antagonist (blocker), vs… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Degarelix is a gonadotropin-releasing hormone receptor antagonist (blocker) with rapid onset of action suppressing… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE To establish a panel of human breast cancer (HBC) xenografts in immunodeficient mice suitable for pharmacologic… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2006
Review
2006
Ferring Research Ltd and licensee Astellas Pharma Inc are developing the gonadotropin-releasing hormone antagonist degarelix as a… (More)
Is this relevant?
2004
2004
Purpose. The objective of this study is to develop a population pharmacokinetic (PK) model that describes the subcutaneous (SC… (More)
  • table I
  • figure 1
  • table II
  • figure 2
  • figure 3
Is this relevant?
2002
2002
We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?